Efficacy and Safety of the Chinese Patent Medicine Yuquan Pill on Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis

Table 2

Characteristics of the studies included in this meta-analysis.

Author, year	Age (T/C)	Number (T/C)	Duration of disease (T/C)	Gender (F/M)	Intervention (T)	Intervention (C)	Course	Outcomes	Region
Zheng and Huang, 2005	46.84 ± 12.52/47.59 ± 11.98	32/30	11.25 ± 9.72 y/11.82 ± 8.13 y	32/30	YQP (8 pills, tid)+metformin/gliclazide	Metformin/gliclazide	NR	①③	Hefei, Anhui
Deng et al., 2006	50 ± 11.6/49.8 ± 12.1	60/30	3.68 ± 2.56 y/3.43 ± 2.12 y	51/39	YQP (6 g, qid)+acarbose (50 mg, tid)	Acarbose (50 mg, tid)	12 w	①②⑤⑥⑦	Hangzhou, Zhejiang
Zhao et al., 2008	41.1 ± 10.4/42.3 ± 11.7	48/46	5.2 ± 3.3 y/4.9 ± 3.2 y	53/41	YQP (8 pills, tid)+metformin (0.25 g, tid)	Metformin (0.25 g, tid)	8 w	①②③⑥	Changsha, Hunan
Li and Wu, 2012	51.5 ± 4/53.5 ± 5.5	50/50	4.8 ± 0.9 y/5.1 ± 1.2 y	53/47	YQP (6 g, qid)+metformin (0.5 g, bid)	Metformin (0.5 g, bid)	6 w	①②③⑥	Weinan, Shanxi
Tian, 2013	49.1 ± 4.7/48.3 ± 5.4	30/30	7.1 ± 0.6 y/6.6 ± 1 y	28/32	YQP decoction + hypoglycemic drugs	Hypoglycemic drugs	4 w	①②⑦	Zhengzhou, Henan
Zhu, 2015	52.3 ± 5.1/53.1 ± 3.4	37/32	9.5 ± 2.1 y/10.5 ± 1.5 y	41/28	YQP (6 g, qid)+acarbose (50 mg, tid)	Acarbose (50 mg, tid)	4 w	②④⑦	Wulanchabu, Neimenggu
Wang, 2017	56.27 ± 6.6/57.31 ± 4.2	60/60	5.56 ± 2.35 y/5.45 ± 2.56 y	66/54	YQP (6 g, qid)+metformin enteric capsules (0.5 g, tid)+ insulin	Metformin enteric capsules (0.5 g, tid)+ insulin	12 w	①③⑤⑥⑦	Tianjin
Jing et al., 2019	46.87 ± 7.14/46.95 ± 7.54	40/40	NR	55/25	YQP (6 g, qid)+metformin/gliclazide/insulin	Metformin/gliclazide/insulin	12 w	①②④⑦	Taiyuan, Shanxi
Xiao et al., 2021	68.9 ± 5.2/69.7 ± 5.5	49/49	5.9 ± 1.8 y/5.6 ± 1.6 y	57/41	YQP (6 g, qid)+saxagliptin (5 mg, qd)	Saxagliptin (5 mg, qd)	12 w	①②③④⑤⑥⑦	Nanyang, Henan
Wan et al., 2021	49.59 ± 5.37/49.65 ± 6.29	49/49	5.14 ± 0.92 y/5.24 ± 0.84 y	58/40	YQP (6 g, qid)+dapagliflozin (10 mg, qd)	Dapagliflozin (10 mg, qd)	12 w	①②③⑤⑥⑦	Zhengzhou, Henan

T: treatment group; C: control group; YQP : Yuquan Pill; F: female; M: male; NR: not reported; Y: year; W: week; ①: fasting blood glucose; ②: two-hour postprandial glucose; ③: glycosylated hemoglobin; ④: total cholesterol; ⑤: c-reactive protein; ⑥: overall effective rate; ⑦: adverse effects.